PD-L1 Testing: A Critical Step for Your Patients With Metastatic Triple-Negative Breast Cancer
Determining PD-L1 status can identify patients who are eligible for TECENTRIQ + nab-paclitaxel (nab-pac) 2
- Metastatic TNBC has historically been an area of serious unmet need, with limited targeted therapy options 5,6
PD-L1 expression on tumor-infiltrating immune cells (IC) as a biomarker for TECENTRIQ in metastatic triple-negative breast cancer (mTNBC) 2
- Tumor and immune cells in the tumor microenvironment both play an important role in immune evasion and tumor progression 7
- PD-L1 expression on IC is a key player in regulating anticancer immunity and can predict response to cancer immunotherapy 8
PFS results in the PD-L1+ population led to the accelerated approval
of TECENTRIQ + nab-pac in PD-L1+ mTNBC 2
- 41% of patients in the trial were PD-L1+ (n=369/902), defined as PD-L1–stained IC of any intensity covering ≥1% of the tumor area*
PD-L1 expression on IC with the VENTANA PD-L1 (SP142) Assay
PD-L1=programmed death-ligand 1.
*As determined by the VENTANA PD-L1 (SP142) Assay.
Test for PD-L1 to identify patients who could benefit from TECENTRIQ + nab-pac in 1L mTNBC
- VENTANA PD-L1 (SP142) is the first and only FDA-approved assay for mTNBC, designed to stain PD-L1 on IC 9-11
- Talk to your pathologists about adding PD-L1 to the biomarker panel for mTNBC, so that your patients are automatically tested
- Select labs or diagnostic centers can also perform PD-L1 testing using SP142, the FDA-approved companion diagnostic for TECENTRIQ in mTNBC